Previous 10 | Next 10 |
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread...
Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced that it will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market o...
Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to pre...
Analysis of the first subset of linked SEER patient data demonstrates DecisionDx®-Melanoma testing was associated with improved overall survival rates compared to untested patients DecisionDx-Melanoma stratifies patient risk of death in an unselected, prospectively tested...
Award recognizes Castle’s commitment to a culture of transparency, teamwork and professional growth Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced that...
Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, will present data highlighting its portfolio of skin cancer tests at Maui Derm for Dermatologists 2022, being held Jan. 24-28, 2022, in Mau...
Clinical performance study published in Future Oncology reinforces the independent value of DecisionDx-SCC to inform risk-appropriate patient management decisions Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient o...
DecisionDx-UM Seq identified somatic mutations relevant to uveal melanoma and is indicated as a complement to DecisionDx ® -UM and DecisionDx ® -PRAME, using the same biopsy tissue Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transformin...
2021 Estimated revenue is expected to meet or exceed top end of guided range of $89-93 million Delivered 28,118 gene expression profile test reports in 2021, an increase of 55% compared to 2020 Year-end 2021 cash and cash equivalents expected to be approximately $330 m...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to presen...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...